NEW YORK (GenomeWeb News) – CollabRx said today that it has signed a multi-year agreement with cancer diagnostics firm Cynvenio Biosystems, under which Cynvenio will use CollabRx's technology and content resources to interpret data from the sequencing-based tests its provides.
Under the terms of the agreement, Cynvenio will use CollabRx's newly launched Genetic Variant Annotation (GVA) service to generate reports for its ClearID Breast Cancer blood test, which is used to monitor breast cancer survivors at high risk of recurrence. ClearID uses next-generation sequencing to identify circulating tumor cells carrying cancer-associated mutations.
Cynvenio will be able to combine test results with clinically actionable data provided by the GVA service, said CollabRx. The GVA service includes a database of information on the clinical impact of cancer genetic profiles and associated therapeutic strategies.
Commenting on the partnership, Cynvenio CEO Andre de Fusco said in a statement that CollabRx's GVA provides "key elements" of its reporting solution. Specifically, it enables the "contextualized interpretation of sequencing results [that] is required to make the results of genomic tests actionable for physicians providing highly personalized cancer treatments to their patients."
The alliance is also an opportunity for CollabRx to expand its services to cover "liquid biopsy" for the first time, Thomas Mika, the company's chairman, president and CEO, noted.